Literature DB >> 2785598

Pulmonary function in patients presenting with Raynaud's phenomenon without an underlying connective tissue disease. A prospective, longitudinal study.

R Aalbers1, H Groen, D S Postma, T W Van der Mark, A A Wouda, R P Reig, C G Kallenberg.   

Abstract

Forty-two patients presenting with Raynaud's phenomenon (RP) were prospectively evaluated for pulmonary function changes over a 6-year followup period. Fifteen patients had secondary RP at presentation, 27 patients had nonsecondary RP. In the latter group, decreased pulmonary diffusing capacity (Tlco) was observed in only 2 patients (7%) whereas 9 patients with secondary RP (60%) had decreased Tlco. In the group of patients with nonsecondary RP exhibiting one or more autoantibodies, Tlco values were lower than in the group without autoantibodies (p less than 0.01). In patients with nonsecondary RP the duration of disease was correlated with the level of Tlco (r = 0.55), probably explained by a higher prevalence of truly primary RP in patients with longstanding nonsecondary RP. During followup no significant changes in pulmonary function were observed in the group with nonsecondary RP. We conclude that pulmonary function testing in patients presenting with nonsecondary RP without autoantibodies does not appear of clinical value.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785598

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  2 in total

1.  Clinical evaluation of scleroderma spectrum disorders using a points system.

Authors:  H Ihn; S Sato; T Tamaki; Y Soma; T Tsuchida; Y Ishibashi; K Takehara
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

2.  The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension.

Authors:  D Mukerjee; L B Yap; V Ong; C P Denton; K Howells; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.